# Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer

> **NCT01207895** · PHASE1 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 5 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DEVICE:** PET imaging with [18F]-FLT
- **DRUG:** [18F]-fluorodeoxythymidine

## Key facts

- **NCT ID:** NCT01207895
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-12
- **Final completion:** 2013-07
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01207895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01207895, "Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01207895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*